Literature DB >> 7430616

All classes of murine IgG antibody mediate macrophage phagocytosis and lysis of erythrocytes.

P Ralph, I Nakoinz, B Diamond, D Yelton.   

Abstract

Antibody-dependent phagocytosis and lysis of sheep RBC by mouse peritoneal exudate cells were studied using IgG subclass fractions of sera prepared by protein A-Sepharose chromatography. Three IgG1, 3 IgG2a, 4 IgG2b, and 1 IgG3 hybridoma antibodies to RBC were also used. The results showed that some monoclonal IgG2a and IgG2b antibodies were more active than IgG1 or IgG3 preparations when normalized to hemagglutinating activity, but all IgG sources mediated both effector mechanisms. This is in accord with findings of strong Fc receptors on macrophages for the IgG2 isotypes and weaker binding by IgG1 and newly discovered IgG3 receptors. A monoclonal IgG2b with no hemagglutination titer showed normal cooperation with macrophages. In contrast, 2 hybridoma IgM were inactive in macrophage-mediated lysis and allowed only marginal ingestion. Similar results were obtained using several macrophage cell lines, mouse spleen and human peripheral blood mononuclear cells, showing that all these types of effector cells do not distinguish among (mouse) IgG subclasses in handling antibody-coated RBC.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7430616

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  In vitro inhibition of tumor B cell growth by IgG-BF-producing Fc gamma RII+ T cell hybridoma and by immunoglobulin G-binding factors.

Authors:  C Mathiot; S Amigorena; J Moncuit; C Sautès; W H Fridman; J L Teillaud
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

2.  In-vitro and in-vivo immunobiological properties of murine monoclonal anti-Brucella antibodies.

Authors:  R Adone; F Ciuchini; C Pistoia; G Piccininno
Journal:  Appl Microbiol Biotechnol       Date:  1994-02       Impact factor: 4.813

3.  Antibody-mediated erythrolysis and erythrophagocytosis by human monocytes, macrophages and activated macrophages. Evidence for distinction between involvement of high-affinity and low-affinity receptors for IgG by using different erythroid target cells.

Authors:  S J Rüegg; T W Jungi
Journal:  Immunology       Date:  1988-03       Impact factor: 7.397

4.  Immunoglobulin Fc receptor molecules on Xenopus laevis splenocytes.

Authors:  V Coosemans; I Hadji-Azimi
Journal:  Immunology       Date:  1988-12       Impact factor: 7.397

5.  Opsonic, cytotoxic, precipitating, blocking of bacterial adherence, and other activities of monoclonal IgE antibody compared with IgA and IgM.

Authors:  H Tlaskalová-Hogenová; J Simecková; V Vĕtvicka; L Fornůsek; M TalaFantová; P Mancal
Journal:  Immunology       Date:  1984-11       Impact factor: 7.397

Review 6.  Fc receptor--more answers, more questions.

Authors:  L Fornůsek; V Vĕtvicka
Journal:  Folia Microbiol (Praha)       Date:  1984       Impact factor: 2.099

7.  A monoclonal antibody to the carbohydrate chain on human hepatocellular carcinoma-associated antigen which suppressed tumor growth in nude mice.

Authors:  Y Fukuda; K Imai; K Miura; M Matsui; T Nakanishi; H Nakazato; J Masukawa; T Higashide; Y Hinoda; T Noguchi
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

8.  Cure of Trypanosoma musculi infection by heat-labile activity in immune plasma.

Authors:  D S Wechsler; P A Kongshavn
Journal:  Infect Immun       Date:  1984-06       Impact factor: 3.441

9.  Fc receptors on mouse neutrophils and eosinophils: antigenic characteristics, isotype specificity and relative cell membrane density measured by flow cytometry.

Authors:  A F López; F L Battye; M A Vadas
Journal:  Immunology       Date:  1985-05       Impact factor: 7.397

10.  Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity.

Authors:  Mingjun Zhang; Jianfei Qian; Yongsheng Lan; Yong Lu; Haiyan Li; Bangxing Hong; Yuhuan Zheng; Jin He; Jing Yang; Qing Yi
Journal:  Int J Cancer       Date:  2014-02-07       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.